Somewhat Positive Media Coverage Somewhat Unlikely to Affect Galmed Pharmaceuticals (GLMD) Share Price

Headlines about Galmed Pharmaceuticals (NASDAQ:GLMD) have been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 47.3095330052374 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several research firms recently commented on GLMD. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Wednesday, January 10th. ValuEngine upgraded Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Maxim Group set a $14.00 price objective on Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, HC Wainwright upped their price objective on Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.40.

How to Become a New Pot Stock Millionaire

Galmed Pharmaceuticals stock traded down $0.09 on Friday, hitting $5.92. The stock had a trading volume of 27,801 shares, compared to its average volume of 52,807. Galmed Pharmaceuticals has a 1 year low of $3.61 and a 1 year high of $12.22. The stock has a market cap of $85.67, a PE ratio of -6.04 and a beta of 2.91.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Galmed Pharmaceuticals had a negative return on equity of 133.50% and a negative net margin of 1,133.55%. The firm had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. equities analysts anticipate that Galmed Pharmaceuticals will post -0.77 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3299738/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-galmed-pharmaceuticals-glmd-share-price.html.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Insider Buying and Selling by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$262.66 Million in Sales Expected for Voya Financial  This Quarter
$262.66 Million in Sales Expected for Voya Financial This Quarter
Zacks: Analysts Expect ICF  Will Post Quarterly Sales of $304.14 Million
Zacks: Analysts Expect ICF Will Post Quarterly Sales of $304.14 Million
American Ecology Co.  Expected to Post Quarterly Sales of $114.50 Million
American Ecology Co. Expected to Post Quarterly Sales of $114.50 Million
First Busey  Issues Quarterly  Earnings Results
First Busey Issues Quarterly Earnings Results
Investment Analysts’ Recent Ratings Updates for Barclays
Investment Analysts’ Recent Ratings Updates for Barclays
SpreadCoin  Price Reaches $0.63
SpreadCoin Price Reaches $0.63


© 2006-2018 Ticker Report. Google+.